Erratum: Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm (European Journal of Nuclear Medicine and Molecular Imaging DOI:10.1007/s00259-009-1302-y);Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 4, 2010, Pages 685-690

  Yamane, Tomohiko ^a   Sakamoto, Setsu ^b   Senda, Michio ^a  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain neoplasm; Clinical impact; Positron emission tomography (PET)

Indexed keywords

METHIONINE C 11;

ADOLESCENT; ADULT; AGED; BRAIN SCINTISCANNING; CANCER DIAGNOSIS; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; RADIATION NECROSIS; RECURRENT CANCER; REVIEW; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

EID: 77952095858     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1372-x     Document Type: Erratum

References (36)

1. 11C] methionine into astrocytomas and oligodendrogliomas J Neurooncol 93 233 241 10.1007/s11060-008-9767-2 1:CAS:528:DC%2BD1MXlvFOms78%3D 19099197
2. 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity AJNR Am J Neuroradiol 29 1867 1871 10.3174/ajnr.A1242 1:STN:280:DC%2BD1cjjs1Oquw%3D%3D 18687745
3. 11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology Clin Cancer Res 10 7163 7170 10.1158/1078-0432.CCR-04-0262 1:CAS:528: DC%2BD2cXpsVKltLY%3D 15534088 (Pubitemid 39487701)
4. 11C methionine positron emission tomography (PET) data - results of a pilot study in 32 surgical cases Acta Neurochir (Wien) 144 777 782 10.1007/s00701-002-0942-5 1:STN:280: DC%2BD38visVaksw%3D%3D (Pubitemid 34985271)
5. 11C-methionine PET for differential diagnosis of low-grade gliomas Neurology 50 1316 1322 1:STN:280:DyaK1c3lsFCiuw%3D%3D 9595980 (Pubitemid 28240345)
6. 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy J Nucl Med 49 694 699 10.2967/jnumed.107.048082 18413375 (Pubitemid 351717532)
7. N Tsuyuguchi T Takami I Sunada Y Iwai K Yamanaka K Tanaka, et al. 2004 Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma Ann Nucl Med 18 291 296 10.1007/BF02984466 1:CAS:528:DC%2BD2cXpsVGit7c%3D 15359921 (Pubitemid 39100096)
8. N Tsuyuguchi I Sunada Y Iwai K Yamanaka K Tanaka T Takami, et al. 2003 Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 98 1056 1064 10.3171/jns.2003.98.5.1056 12744366 (Pubitemid 36460897)
9. O De Witte I Goldberg D Wikler S Rorive P Damhaut M Monclus, et al. 2001 Positron emission tomography with injection of methionine as a prognostic factor in glioma J Neurosurg 95 746 750 10.3171/jns.2001.95.5.0746 11702862 (Pubitemid 33043345)
10. 11C-methionine and survival in patients with low-grade gliomas Cancer 92 1541 1549 10.1002/1097-0142(20010915)92: 6<1541::AID-CNCR1480>3.0.CO;2-D 1:STN:280:DC%2BD3MnpsFKhtA%3D%3D 11745233 (Pubitemid 32947840)
11. M Matsuo K Miwa J Shinoda N Kako H Nishibori K Sakurai, et al. 2009 Target definition by C11-methionine-PET for the radiotherapy of brain metastases Int J Radiat Oncol Biol Phys 74 714 722 1:CAS:528:DC%2BD1MXmsFyiu7k%3D 19095373
12. 11C-methionine PET with reference to a normal methionine uptake map J Nucl Med 48 1971 1980 10.2967/jnumed.107.043240 1:CAS:528:DC%2BD1cXnvFSnsQ%3D%3D 18006617 (Pubitemid 350232305)
13. B Pirotte S Goldman O Dewitte N Massager D Wikler F Lefranc, et al. 2006 Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures J Neurosurg 104 238 253 10.3171/jns.2006.104.2.238 16509498 (Pubitemid 43304323)
14. 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies J Neurosurg 101 476 483 10.3171/jns.2004.101.3.0476 1:CAS:528:DC%2BD2cXnslynsLg%3D 15352606 (Pubitemid 39100725)
15. BE Hillner BA Siegel D Liu AF Shields IF Gareen L Hanna, et al. 2008 Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry J Clin Oncol 26 2155 2161 10.1200/JCO.2007.14.5631 18362365
16. BE Chatterton I Ho Shon A Baldey N Lenzo A Patrikeos B Kelley, et al. 2009 Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study Eur J Nucl Med Mol Imaging 36 354 361 10.1007/s00259-008-0959- y 1:STN:280:DC%2BD1M7kt1Wqug%3D%3D 18931839
17. AM Scott DH Gunawardana J Wong I Kirkwood RJ Hicks I Ho Shon, et al. 2009 Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study Eur J Nucl Med Mol Imaging 36 347 353 10.1007/s00259-008-0958-z 18931840
18. AM Scott DH Gunawardana B Kelley JG Stuckey AJ Byrne JE Ramshaw, et al. 2008 PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study J Nucl Med 49 1451 1457 10.2967/jnumed.108.051615 18703607
19. AM Scott DH Gunawardana D Bartholomeusz JE Ramshaw P Lin 2008 PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study J Nucl Med 49 1593 1600 10.2967/jnumed.108.053660 18794254
20. Y Nakamoto K Togashi T Kaneta H Fukuda K Nakajima K Kitajima, et al. 2009 Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study Jpn J Clin Oncol 39 297 302 10.1093/jjco/hyp010 19269991
21. 11C-choline positron-emission tomography AJNR Am J Neuroradiol 29 1176 1182 10.3174/ajnr.A1008 1:STN:280:DC%2BD1cznsFWgtw%3D%3D 18388218 (Pubitemid 351954890)
22. 18F-FDG-PET Mol Imaging Biol 10 281 287 10.1007/s11307-008-0152-5 1:STN:280:DC%2BD1cvpvVygtQ%3D%3D 18543041
23. 18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme J Neurooncol 84 305 314 10.1007/s11060-007-9375-6 17492401
24. AJ Kumar NE Leeds GN Fuller P Van Tassel MH Maor RE Sawaya, et al. 2000 Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment Radiology 217 377 384 1:STN:280:DC%2BD3crhtFeqsg%3D%3D 11058631
25. ME Mullins GD Barest PW Schaefer FH Hochberg RG Gonzalez MH Lev 2005 Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis AJNR Am J Neuroradiol 26 1967 1972 16155144
26. JP Rock L Scarpace D Hearshen J Gutierrez JL Fisher M Rosenblum, et al. 2004 Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis Neurosurgery 54 1111 1117 10.1227/01.NEU.0000119328.56431.A7 15113465 (Pubitemid 38585925)
27. T Sugahara Y Korogi S Tomiguchi Y Shigematsu I Ikushima T Kira, et al. 2000 Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue AJNR Am J Neuroradiol 21 901 909 1:STN:280:DC%2BD3c3ntlSrug%3D%3D 10815666 (Pubitemid 30262837)
28. D Croteau L Scarpace D Hearshen J Gutierrez JL Fisher JP Rock, et al. 2001 Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma Neurosurgery 49 823 829 10.1097/00006123-200110000-00008 1:STN:280:DC%2BD3Mrhslyqsg%3D%3D 11564242 (Pubitemid 32927953)
29. 11C-choline positron-emission tomography AJNR Am J Neuroradiol 29 1176 1182 10.3174/ajnr.A1008 1:STN:280:DC%2BD1cznsFWgtw%3D%3D 18388218 (Pubitemid 351954890)
30. 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors Eur J Nucl Med Mol Imaging 31 1064 1072 1:CAS:528: DC%2BD2cXmtFWks7w%3D 15014903 (Pubitemid 39050172)
31. 18F-FDG-PET Mol Imaging Biol 10 281 287 10.1007/s11307-008-0152-5 1:STN:280:DC%2BD1cvpvVygtQ%3D%3D 18543041
32. G Pöpperl FW Kreth JH Mehrkens J Herms K Seelos W Koch, et al. 2007 FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading Eur J Nucl Med Mol Imaging 34 1933 1942 10.1007/s00259-007-0534-y 17763848 (Pubitemid 350212135)
33. 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma Eur J Nucl Med Mol Imaging 35 2009 2017 10.1007/s00259-008-0847-5 1:CAS:528:DC%2BD1cXht1artLzK 18542957
34. 18F-FDG J Nucl Med 46 945 952 1:CAS:528: DC%2BD28XitFSqtrw%3D 15937304 (Pubitemid 43733508)
35. AH Kaye DG Walker 2000 Low-grade astrocytomas: controversies in management J Clin Neuroscience 7 475 483 10.1054/jocn.2000.0774 1:STN:280:DC%2BD3MzgsVWhtg%3D%3D
36. 11C-methyl-L-methionine positron emission tomography in patients with primary cerebral malignant lymphoma Neuroradiology 34 517 519 10.1007/BF00598964 1:STN:280: DyaK3s%2Fmtlyjug%3D%3D 1436463